全文获取类型
收费全文 | 308184篇 |
免费 | 18180篇 |
国内免费 | 437篇 |
专业分类
耳鼻咽喉 | 4635篇 |
儿科学 | 11367篇 |
妇产科学 | 10690篇 |
基础医学 | 45677篇 |
口腔科学 | 8319篇 |
临床医学 | 25034篇 |
内科学 | 57856篇 |
皮肤病学 | 6623篇 |
神经病学 | 21820篇 |
特种医学 | 12164篇 |
外国民族医学 | 43篇 |
外科学 | 49295篇 |
综合类 | 7908篇 |
现状与发展 | 1篇 |
一般理论 | 167篇 |
预防医学 | 20317篇 |
眼科学 | 7331篇 |
药学 | 21793篇 |
中国医学 | 853篇 |
肿瘤学 | 14908篇 |
出版年
2021年 | 2432篇 |
2019年 | 2458篇 |
2018年 | 4022篇 |
2017年 | 3011篇 |
2016年 | 3512篇 |
2015年 | 3798篇 |
2014年 | 5039篇 |
2013年 | 7882篇 |
2012年 | 9804篇 |
2011年 | 10318篇 |
2010年 | 6609篇 |
2009年 | 5821篇 |
2008年 | 9460篇 |
2007年 | 10301篇 |
2006年 | 10159篇 |
2005年 | 9741篇 |
2004年 | 9503篇 |
2003年 | 8944篇 |
2002年 | 8510篇 |
2001年 | 13689篇 |
2000年 | 14060篇 |
1999年 | 11662篇 |
1998年 | 3102篇 |
1997年 | 2869篇 |
1996年 | 2711篇 |
1995年 | 2578篇 |
1992年 | 8333篇 |
1991年 | 8464篇 |
1990年 | 8269篇 |
1989年 | 8087篇 |
1988年 | 7323篇 |
1987年 | 7084篇 |
1986年 | 6726篇 |
1985年 | 6521篇 |
1984年 | 4767篇 |
1983年 | 4121篇 |
1982年 | 2474篇 |
1979年 | 4433篇 |
1978年 | 3231篇 |
1977年 | 2740篇 |
1976年 | 2503篇 |
1975年 | 2836篇 |
1974年 | 3362篇 |
1973年 | 3368篇 |
1972年 | 3124篇 |
1971年 | 2952篇 |
1970年 | 2840篇 |
1969年 | 2583篇 |
1968年 | 2541篇 |
1967年 | 2377篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
22.
AbstractWe have investigated communication preferences of mammography results in 90 patients through a structured interview approach. About 81% of patients expressed that they wanted to get the results, and 18% expressed that getting the results does not help if they are incomprehensible. In patients who want to get the results, 80% preferred face-to-face interaction with physicians, whereas the others preferred other modes of communication to prevent loss of time. Majority of patients infavor of face-to-face interaction (57%) preferred both the referring physician and the radiologist. Comprehensibility and fast delivery of reports, plus direct communication with radiologists are the requirements in mammography patients while implementing patient-centered radiology. 相似文献
23.
24.
25.
26.
Are Dermatophytid Reactions in Patients with Kerion Celsi Much More Common Than Previously Thought? A Prospective Study
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Dermatophytid reactions are secondary eruptions in response to dermatophytosis. Only a few cases demonstrating an association between dermatophytid reactions and tinea capitis have been reported. Dermatophytid reactions were evaluated in patients diagnosed with kerion celsi. Patients admitted to the dermatology clinic of Van Regional Training and Research Hospital between November 22, 2012, and July 1, 2013, diagnosed with kerion celsi were evaluated for dermatophytid reactions. Six girls (32%) and 13 boys (68%) were included in this study. Dermatophytid reactions were detected in 13 of the 19 patients (68%). Seven patients (36.84%) had eczematous patches or plaques and three (15.8%) had papules. Eczematous lesions, papules, and pustules were noted in two patients (10.5%) and one (5.3%) had signs of an angioedema‐like reaction. Dermatophytid reactions in all patients were observed before the initiation of therapy. According to our clinical experiences, dermatophytid reactions in patients with kerion celsi were more common than reported. Eczematous scaly patches or plaques were the most frequently seen forms of dermatophytid in patients with kerion celsi. Dermatophytid reactions may occur before or after initiation of systemic antifungal therapy. Recognition of this reaction is important so that dermatophytids can be distinguished from drug reactions and the decision can be made whether to continue or to stop the systemic antifungal treatment. 相似文献
27.
28.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
29.